ACET Adicet Bio Inc
3,412
$1.60
$0.03
(1.91%)
| Watchers | 3,412 |
| 52-Wk Low | $1.10 |
| 52-Wk High | $6.65 |
| Market Cap | $131.48M |
| Volume | 1.06M |
| 52-Wk High | $6.65 |
| 52-Wk Low | $1.10 |
Adicet Reports First Quarter 2024 Financial Results and Provides Business UpdatesBusiness Wire • 4 days ago
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial...
Share to Feed
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that an...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...
HC Wainwright reissued their buy rating on shares of Adicet Bio (NASDAQ:ACET - Free Report) in a research report report published on Tuesday, Benzinga reports. They currently have a $10.00 price...
Adicet Bio (NASDAQ:ACET - Get Free Report)s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...
Apogee Therapeutics Inc. APGE, a clinical-stage company, is focused on developing novel therapies for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease...